A Polar Substituent-Containing Acylation Agent for the Radioiodination of Internalizing Monoclonal Antibodies: N-Succinimidyl 4-Guanidinomethyl-3-[131I]iodobenzoate ([131I]SGMIB)-Reference-Cited by-同舟云学术

A Polar Substituent-Containing Acylation Agent for the Radioiodination of Internalizing Monoclonal Antibodies: N-Succinimidyl 4-Guanidinomethyl-3-[131I]iodobenzoate ([131I]SGMIB)

Published:2001-04-19 Issue:3 Volume:12 Page:428-438
ISSN:1043-1802
Container-title:Bioconjugate Chemistry
language:en
Short-container-title:Bioconjugate Chem.

Author:

Vaidyanathan Ganesan¹,Affleck Donna J.¹,Li Jean¹,Welsh Phil¹,Zalutsky Michael R.¹

Affiliation:

1. Department of Radiology, Duke University Medical Center, Durham, North Carolina 27710

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Pharmaceutical Science,Pharmacology,Biomedical Engineering,Bioengineering,Biotechnology

Link

https://pubs.acs.org/doi/pdf/10.1021/bc0001490

Reference41 articles.

1. Ali, S. A., Warren, S. D., Richter, K. Y., Badger, C. C., Eary, J. F., Press, O. W., Krohn, K. A., Bernstein, I. D., and Nelp, W. B. (1990) Improving the tumor retention of radioiodinated antibody: aryl carbohydrate adducts.Cancer Res.50(suppl.), 783s−788s.

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PSMA-reactive NB7 single domain antibody fragment: A potential scaffold for developing prostate cancer theranostics;Nuclear Medicine and Biology;2024-07

2. Radioiodine based biomedical carriers for cancer theranostics;Coordination Chemistry Reviews;2023-12

3. Development of Novel Trifunctional Chelating Agents That Enhance Tumor Retention of Radioimmunoconjugates;Journal of Medicinal Chemistry;2023-09-18

4. Site-Specific Radiohalogenation of a HER2-Targeted Single-Domain Antibody Fragment Using a Novel Residualizing Prosthetic Agent;Journal of Medicinal Chemistry;2022-11-11

5. Highly effective liquid and solid phase extraction methods to concentrate radioiodine isotopes for radioiodination chemistry;Journal of Labelled Compounds and Radiopharmaceuticals;2022-08